Migraine: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CGRP 19
• HMGB1 0
• NOTCH3 0
• GLP-1 0
• MAPK 0
• PI3K 0
• IL-17 0
• IL-6 1
• TNF 1
• PPAR 0
• TREM2 0
• COX-2 0
• IL-4 0
• STING 0
• AKT 0
• AMPK 0
• AQP4 0
• ERK 0
• GIP 0
• GPX4 0
• HIF-1 0
• IL-1 1
• mTOR 0
• NLRP3 0
• NMDA 0
• PD-1 0
• SCN1A 0
• SCN2A 0
• STAT3 0
• VEGF 0

16 of 16+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-JU-IA

  closed-loop IMPlantable tHerapeutic neurOmodulation systems enabled by advanced micRoelectronics and Innovative pAckaging (IMPHORIA)

  Salvia Bioelectronics Bv· Eindhoven, Netherlands· EU contribution €4,567,844· until Apr 2029· 5 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Hospital@Home: Person-centered Digital Transformation for Integrated Home Care (HospitalAtHome)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €14,179,766· until Dec 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Combinatorial use of cannabidiol and the serine hydrolase inhibitor AKU-005 to enhance endocannabinoids for treatment of migraine (Migraine cannabinoid)

  King's College London· London, United Kingdom· EU contribution €454,103· until Jun 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  INNOVATIVE SOLUTION OF ELECTRO-FOCUS EYEGLASSES (I-SEE)

  Laclaree· Lyon, France· EU contribution €2,499,999· until Nov 2026

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  A mechanism-based approach to the prevention of chronic pain and its comorbid mental disorders (MECHPAIN)

  Zentralinstitut Fuer Seelische Gesundheit· Mannheim, Germany· EU contribution €2,424,481· until Sept 2029

  The disease is named only in the funder's project summary, not in the title.

5 of 6 running projects, newest first. Listed amounts together: €26.6m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Acute Migraine Treatment in the ED With Gepants

  NCT06985342· Icahn School of Medicine at Mount Sinai· Updated 29 Apr 2026

  “Study closing at current site. Study to start as new at different site.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

  NCT06103734· Pfizer· Updated 13 Jan 2026

  “Strategic decision to cancel the study based on adjusted clinical development plan.”Registry text, quoted unchanged. Source

• Terminated

  A Study With Intranasal Kinetic Oscillation Stimulation (KOS) in the Prevention of Chronic Migraine

  NCT05273151· Chordate Medical· Updated 31 Jul 2025

  “Slow inclusion due to new treatment (Gepants)”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

  NCT06103734· Pfizer· Source

• Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide

  NCT07021859· Danish Headache Center· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 33
• Gene Expression Profiling 8
• Sequence Analysis, RNA 2
• Exome Sequencing 5
• Proteomics 6
• Metabolomics 6
• Mass Spectrometry 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 136
• Machine Learning 32
• Deep Learning 1
• Cohort Studies 82
• Genome-Wide Association Study 40

• Subclinical Cerebral Lesions in Migraine: A Proof-of-Concept Study on Platelet Aggregation.

  Eur J Neurol, Nov 2026

• Assessment of Cerebral Perfusion Asymmetry in Chronic Migraine Patients Using Intravoxel Incoherent Motion (IVIM)-Derived Pseudodiffusion Coefficient and Perfusion Fraction.

  NMR Biomed, Nov 2026

• Is photophobia associated with the structure of the visual thalamus? A MRI morphometric study.

  Neurol Sci, Oct 2026

• A Standardized Workflow for Multimodal Assessment of Right-to-Left Shunt-Related Ischemic Brain Injury.

  J Vis Exp, Oct 2026

• Multimodal convergence is needed before inferring neuroaxonal injury in migraine.

  J Headache Pain, Oct 2026

• Multimodal 7T MRI reveals subcortical structural, functional, iron accumulation, and glymphatic abnormalities in chronic migraine.

  Cephalalgia, Sept 2026

• Hypothalamic subregional volume in relation to VSS-C total symptom burden in women with migraine: an exploratory cross-sectional MRI study.

  Front Neurol, Sept 2026

• Chronic relapsing inflammatory optic neuropathy misdiagnosed as intermittent angle closure: a diagnostic challenge.

  BMJ Case Rep, Sept 2026

• Neurological involvement in localized scleroderma: a systematic review of clinical manifestations and neuroimaging findings.

  Front Immunol, Sept 2026

• Resting-state fMRI correlates of acupuncture in migraine: a coordinate-based meta-analysis.

  J Oral Facial Pain Headache, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.